23 completed, 9 recruiting, 9 terminated, 7 unknown. 62 Phase 2, 5 Phase 1, 1 Phase 3.
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas Sacituzumab Tirumotecan (Sac-TMT) - Unresectable Thymic Carcinoma | Phase 2 | Not yet recruiting | National Cancer Center, Japan | 35 | 2027-02-01 | 2026-08-06 |
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-11 | 2026-11-06 |
| Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan-beam CT for Thymoma With Pleural Metastasis hypofractionated radiotherapy guided by optical surface imaging and FBCT, hypofractionated radiotherapy guided by CBCT - Thymoma and Thymic Carcinoma, Pleural Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 234 | 2026-10-12 | 2026-10-16 |
| Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma adebrelimab plus chemoradiation - Thymic Carcinoma | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 31 | 2026-04-01 | 2026-03-18 |
| Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma Sacituzumab tirumotecan - Thymic Carcinoma | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 30 | 2026-03-13 | 2026-08-12 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
| 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors Cyclophosphamide, Doxorubicin, and Cisplatin (CAP), nab-Paclitaxel and Carboplatin - Thymoma and Thymic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 116 | 2026-03-01 | 2026-03-11 |
| HEARTS Trial for Thoracic Cancers MRgART, LINAC - Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III | Phase 2 | Suspended | University of Wisconsin, Madison | 60 | 2025-10-08 | 2026-10-30 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma Experimental: tislelizumab+anlotinib - Thymic Carcinoma, Thymoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 20 | 2025-03-31 | 2025-12-01 |
| Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma Radiotherapy, Concurrent chemotherapy, Methylprednisolone - Thymoma | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2024-11-20 | 2024-12-12 |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors Sacituzumab govitecan-hziy - Thymoma, Thymic Carcinoma | Phase 2 | Recruiting | Georgetown University | 18 | 2024-04-25 | 2026-09-11 |
| Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors carbon ion radiotherapy - Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy | Phase 2 | Recruiting | Jian Chen | 48 | 2024-01-26 | 2025-06-13 |
| Neoadjuvant Treatment For Locally Advanced Thymic Cancer Envolizumab combined with radiotherapy - Thymic Carcinoma | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 25 | 2023-11-04 | 2026-05-08 |
| First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) MK-3475, Lenvatinib, Carboplatin - Untreated Advanced or Recurrent Thymic Carcinomas | Phase 2 | Recruiting | National Cancer Center, Japan | 35 | 2023-09-04 | 2023-10-23 |
| The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train. NAB-Paclitaxel plus Cisplatin, Cisplatin plus Epirubicin plus Cyclophosphamide - Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma | Phase 2 | Unknown | Peng Liu | 50 | 2023-04-30 | 2023-04-18 |
| PT-112 in Subjects With Thymoma and Thymic Carcinoma PT-112 - Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 53 | 2022-04-06 | 2026-10-16 |
| A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors KN046 - Thymic Carcinoma | Phase 2 | Terminated | Weill Medical College of Cornell University | 4 | 2021-12-13 | 2024-04-16 |
| Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents Pembrolizumab, Lenvatinib 10 mg - Metastatic Thymic Carcinoma, Thymoma Type B3 | Phase 2 | Completed | MedSIR | 43 | 2021-09-21 | 2026-02-19 |
| Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma M7824 - Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2020-12-26 | 2026-10-16 |
Showing 20 of 62. Sign in to see all of them.
Thymus Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Small Cell Lung Carcinoma (5) · Thymic epithelial tumor (5) · Neoplasm Metastasis (3) · Esophageal Neoplasms (2) · Lung Neoplasms (2) · Mediastinal Neoplasms (2) · Melanoma (2) · Mesothelioma (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Sarcoma (2) · Adenocarcinoma (1) · Anemia, Refractory (1)
Hemic and Lymphatic Diseases (62) · Lymphatic Diseases (62) · Neoplasms by Histologic Type (62) · Neoplasms by Site (62) · Neoplasms, Complex and Mixed (62) · Thoracic Neoplasms (62) · Neoplasms (61) · Thymus Neoplasms (54) · Respiratory Tract Diseases (10) · Bronchial Neoplasms (8) · Carcinoma, Bronchogenic (8) · Lung Diseases (8) · Respiratory Tract Neoplasms (8) · Lung Neoplasms (6) · Pathologic Processes (5)
Carboplatin (5) · Cyclophosphamide (5) · Sunitinib (5) · Cisplatin (4) · Paclitaxel (4) · pembrolizumab (4) · Nivolumab (3) · Radiotherapy (3) · 130-nm albumin-bound paclitaxel (2) · Chemoradiotherapy (2) · Doxorubicin (2) · Erlotinib Hydrochloride (2) · Methylprednisolone (2) · N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide (2) · Octreotide (2)
National Cancer Institute (NCI) (11) · Georgetown University (3) · Sun Yat-sen University (3) · Eastern Cooperative Oncology Group (2) · National Cancer Center, Japan (2) · Novartis Pharmaceuticals (2) · Patrick Joseph Loehrer Sr. (2) · Tiziana Life Sciences LTD (2) · Armando Santoro, MD (1) · Beijing Biotech (1) · Claudia Proto (1) · Dwight Owen (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Haihe Biopharma Co., Ltd. (1)
United States (31) · China (13) · Italy (7) · France (5) · Japan (2) · South Korea (2) · Spain (2) · Belgium (1) · Canada (1) · Denmark (1) · Germany (1) · Netherlands (1) · South Africa (1) · Switzerland (1) · United Kingdom (1)
Arun Rajan, M.D. (8) · Armando Santoro, MD (2) · Arun Rajan, MD. (2) · Chul Kim, MD (2) · Patrick Loehrer, M.D. (2) · Anne S Tsao (1) · Barbara Jean Bambach, MD (1) · Barbara Ma, MD (1) · Benjamin Besse, MD (1) · Benjamin Besse, MD, PhD (1) · Carri Glide-Hurst, PhD, DABR, FAAPM (1) · Dae Seog Heo, MD, PhD (1) · David S. Ettinger, MD (1) · Deping Zhao, MD,PhD (1) · Dwight Owen, MD (1)
PMID 34393061, PMID 21502559, PMID 21502553, PMID 25403584, PMID 29395863, PMID 10555755, PMID 11123390, PMID 11282421, PMID 12712448, PMID 12778165, PMID 14722038, PMID 14963856, PMID 15201427, PMID 15725919, PMID 17410014, PMID 17570676, PMID 18222230, PMID 18268188, PMID 18596824, PMID 19220526, PMID 19451433, PMID 19461405, PMID 20421818, PMID 20930041, PMID 21847048, PMID 21847058, PMID 21953501, PMID 23860537, PMID 24139613, PMID 24439931, PMID 24974848, PMID 25146529, PMID 25189481, PMID 25202099, PMID 25275083, PMID 25396308, PMID 25396314, PMID 25402569, PMID 25411417, PMID 25592632, PMID 25667274, PMID 25799277, PMID 26009269, PMID 26028668, PMID 26291007, PMID 26314779, PMID 26766736, PMID 27565906, PMID 27844328, PMID 27876674
2009 (1), 2015 (1), 2017 (1), P30CA015083 (1), P30CA016056 (1), R01HL153720 (1), U10CA021115 (1), U10CA180888 (1)